Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Welcome and Introduction to Vi3C

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Jan
19
Today In Oncology
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
HCC LLM Advice and Treatment Concordance
Can a Genetic Variant Affect the Efficacy of Abiraterone
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo